GlassScriptPhysician profile
Lloyd J Taylor
NPI 1932155629
$2,820.89
in general payments reported to CMS, 2019-2025
33 companies · $50.48 in 2025
The $50.48 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,164 · 2022: $903 · 2023: $584 · 2024: $120 · 2025: $50.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $754.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $603.80 | 2021-2023 | |
| Novo Nordisk INC | $181.39 | 2021-2024 | Rybelsus, Wegovy, Ozempic |
| Almatica Pharma LLC | $179.61 | 2021-2024 | Loreev Xr |
| Kowa Pharmaceuticals America, INC. | $163.35 | 2021-2023 | Livalo, Seglentis |
| Lilly USA, LLC | $132.35 | 2021-2024 | Mounjaro |
| Nabriva Therapeutics, Plc | $128.52 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.92 | 2021-2023 | Trintellix |
| Astellas Pharma US INC | $120.82 | 2021 | |
| Hikma Pharmaceuticals USA | $114.93 | 2022-2023 | Mitigare, Ryaltris, Kloxxado |
| Arbor Pharmaceuticals, INC. | $97.43 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.17 | 2021-2023 | Xifaxan, Trulance |
| Amgen INC. | $88.10 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $80.09 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $76.61 | 2021 | |
| Pfizer INC. | $63.73 | 2023-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $60.31 | 2022-2023 | Nuzyra |
| Acerus Pharmaceuticals Corporation | $53.88 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $52.18 | 2021-2022 | |
| Amarin Pharma, INC. | $46.52 | 2021 | |
| Glaxosmithkline, LLC. | $41.92 | 2021-2023 | Trelegy Ellipta |
| Exact Sciences Corporation | $39.29 | 2023 | Cologuard Collection Kit |
| Ironwood Pharmaceuticals, INC | $37.12 | 2021 | |
| Biodelivery Sciences International, INC. | $33.70 | 2021 | |
| Halozyme INC | $32.41 | 2023 | |
| Idorsia Pharmaceuticals US INC | $32.26 | 2023 | Quviviq |
| Eisai INC. | $28.70 | 2021 | |
| Antares Pharma, INC. | $21.55 | 2023 | Nocdurna, Xyosted, Tlando |
| Celgene Corporation | $19.94 | 2025 | Reblozyl |
| Virtus Pharmaceuticals LLC | $19.12 | 2021 | |
| Abbott Laboratories | $16.44 | 2025 | Freestyle Libre 3 |
| Verity Pharmaceuticals INC. | $14.52 | 2024 | Tlando |
| Corcept Therapeutics | $13.30 | 2023 | Korlym |
| Genentech USA, INC. | $9.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lloyd Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.